LLY

1,071.53

+0.34%↑

JNJ

205.37

-0.98%↓

ABBV

229.2

+0.63%↑

UNH

324.87

+0.03%↑

AZN

92.08

+0.63%↑

LLY

1,071.53

+0.34%↑

JNJ

205.37

-0.98%↓

ABBV

229.2

+0.63%↑

UNH

324.87

+0.03%↑

AZN

92.08

+0.63%↑

LLY

1,071.53

+0.34%↑

JNJ

205.37

-0.98%↓

ABBV

229.2

+0.63%↑

UNH

324.87

+0.03%↑

AZN

92.08

+0.63%↑

LLY

1,071.53

+0.34%↑

JNJ

205.37

-0.98%↓

ABBV

229.2

+0.63%↑

UNH

324.87

+0.03%↑

AZN

92.08

+0.63%↑

LLY

1,071.53

+0.34%↑

JNJ

205.37

-0.98%↓

ABBV

229.2

+0.63%↑

UNH

324.87

+0.03%↑

AZN

92.08

+0.63%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

0.95 -12.04

Buy Sell

Overview

Share price change

24h

Current

Min

0.95

Max

1.08

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+376.19% upside

Market Stats
By TradingEconomics
Market Cap	3.5M 129M
Previous open	12.99
Previous close	0.95

News Sentiment

By Acuity

50%

166 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 gru 2025, 23:54 UTC

Major Market Movers

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22 gru 2025, 19:08 UTC

Acquisitions, Mergers, Takeovers

Correction to Alphabet to Buy Intersect Article

22 gru 2025, 17:21 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22 gru 2025, 16:46 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Buy Intersect for $4.75 Billion in Cash

22 gru 2025, 23:50 UTC

Market Talk

Nikkei May Decline as Yen Rebounds -- Market Talk

22 gru 2025, 23:42 UTC

Market Talk

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22 gru 2025, 22:31 UTC

Earnings

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22 gru 2025, 22:31 UTC

Earnings

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22 gru 2025, 22:30 UTC

Earnings

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 gru 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

22 gru 2025, 21:37 UTC

Acquisitions, Mergers, Takeovers

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22 gru 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22 gru 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

Capricorn to Acquire Prospective Package From Tempest Minerals

22 gru 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22 gru 2025, 20:54 UTC

Acquisitions, Mergers, Takeovers

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22 gru 2025, 20:52 UTC

Acquisitions, Mergers, Takeovers

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22 gru 2025, 20:09 UTC

Market Talk

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22 gru 2025, 19:56 UTC

Market Talk

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22 gru 2025, 19:49 UTC

Acquisitions, Mergers, Takeovers

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22 gru 2025, 19:23 UTC

Market Talk

Mexico's Inflation Seen Easing in Early December -- Market Talk

22 gru 2025, 19:23 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 gru 2025, 19:02 UTC

Market Talk

Global Energy Roundup: Market Talk

22 gru 2025, 19:02 UTC

Market Talk

Precious Metals Climb to New Heights -- Market Talk

22 gru 2025, 18:45 UTC

Market Talk

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22 gru 2025, 18:30 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22 gru 2025, 18:23 UTC

Acquisitions, Mergers, Takeovers

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22 gru 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

22 gru 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

22 gru 2025, 17:06 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

376.19% upside

12 Months Forecast

Average 5 USD 376.19%

High 8 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

166 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.